ERBB2 and gastric cancer: The aim of our study is to investigate the efficacy of duligotuzumab or ipatasertib in combination with trastuzumab by evaluating in vitro the antiproliferative, pro-apoptotic and anti-migration effects in HER2-positive gastric cancer cells.